Further studies found that increased MIR17HG expression is associated with a poor prognosis in patients with diverse types of tumours30,31, and single-nucleotide polymorphisms of MIR17HG are associated with a risk of breast cancer development32. Here, MIR17HG is linked to breast cancer.